British medical science magazine:The comprehensive therapy can raise a pancreas cancer a livability

According to the British medical science magazine 《bistoury 》at network electronics version up announce of a clinical research show, the consociation chemotherapy method can raise the death rate very high pancreas cancer the sufferer's livability 100%.

Because most patients while discovering to suffer from a pancreas cancer of the condition has already come to an a later period, many pancreas cancer the sufferer is after being diagnosed to suffer from this kind of malignant disease of the life expect to only have for a few months.Currently to the medium later period pancreas can't carry on surgical operation cancer of standard treatment the method be an usage single of anti-cancer medicine Gemcitabine(the Chinese merchandise name is a Jian Ze Gemzar), this kind of medicine can interfere grow of cancer cell and cause to the pancreas cancer of the symptom have an obvious function, but this kind of treatment method for medium later period the pancreas cancer patient's livability also can't rise valid influence and is diagnose to bring trouble medium later period pancreas the sufferer of the cancer use Jian Ze or so survive after only 20% can be over a year.The recent Italian researcher carried on random clinical studies to 99 pancreas cancer sufferers who would like to accept clinical studies.47 only accept a Jian Ze treatment in 99 sufferers, in addition to using Jian Ze, 52 other patients also combine other medicine, like agreeable platinum and 5 － Fu etc.s.Accept patient's livability of unite the chemotherapy to reach to 40% after a year, but only take patient's livability of Jian Ze 20% only is or so.

This research is learned a Rui Ni by the San raffaele H medical science of the Milan the tumor of the graduate school lead.Because the data amount use by this clinical studies less, so the doctor of Rui Ni suggest to unite a medicine treatment a method at this at become a new standard treatment, method before have to through more extensive III period clinical studies.